
MREO Stock Forecast & Price Target
MREO Analyst Ratings
Bulls say
Mereo BioPharma Group is attractive because setrusumab still shows clinically meaningful fracture and bone mineral density benefits in higher-risk OI patients, and the FDA has signaled openness to alternative fracture analyses that could support a BLA despite the primary endpoint miss. The alvelestat program adds a second value driver in a large unmet-need AATD-LD market, with Sentynl potentially funding development through a $40M upfront/R&D payment, up to $435M in milestones, and double-digit U.S. royalties while Mereo retains ex-U.S. rights. Financially, the company ended 3Q26 with $26.1M in cash and equivalents, guiding runway into late 2027, while partnering activity and late-stage assets provide multiple near- and mid-term catalysts.
Bears say
Mereo BioPharma Group is viewed negatively because setrusumab failed to meet the trial’s key efficacy hurdles in Phase 3 ORBIT, with no statistically significant reduction in annualized fracture rates on either the primary endpoint or the all-fracture secondary endpoint, despite a 159-patient study. Although bone mineral density and some pain or daily activity measures improved, those benefits did not translate into the core clinical outcome needed to support a strong commercial case, especially in a rare disease setting where fracture reduction is critical. The company also remains financially constrained, since it will require additional funds to advance clinical candidates and there is no guarantee it can secure financing on favorable terms, receive milestone payments, or attract new partners.
This aggregate rating is based on analysts' research of Mereo Biopharma Group Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
MREO Analyst Forecast & Price Prediction
Start investing in MREO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Mereo Biopharma Group Plc - ADR (MREO) Forecast
MREO Analyst Forecast & Price Prediction
Start investing in MREO
Order type
Buy in
Order amount
Est. shares
0 shares